Brighter secures external financing of up to SEK 100 million to support the launch of Actiste® and issues free warrants to its shareholders.
Brighter has signed an agreement relating to an investment of up to SEK 100 million. The capital will be used for the production and the launch of Actiste , the company's unique diabetes service. The transaction is carried out through a private placement of convertible notes with warrants attached in up to eight tranches spread over 36 months. The first Tranche issued by Brighter amounts to SEK 30 million. - This investment will enable us to launch and produce Actiste in order to meet the demand. We are pleased to be able to welcome a large international